How Merck KGaA uses light scattering measurements for better developability assessment of biologic therapeutics

November 8, 2021

The ability to monitor biologic candidates' propensity towards self-association is considered critical for predicting whether a therapeutic is likely to aggregate or become difficult to administer due to viscosity.

Because it is neither practical nor cost-effective to consume large quantities of material early in development, measurements are conducted at low concentrations and used to predict how a formulation will behave at higher, more clinically-relevant concentrations.

Precise and reproducible data for these measurements is required for rational decision-making that improves downstream success. 

Read how Merck KGaA uses deviation from linearity derived from light scattering measurements to find the optimal formulation buffer for their biologics candidates, and how these measurements on the Prometheus Panta compare to previously collected data.

Previous Article
5 experiments in biologics that can be improved with dynamic light scattering
5 experiments in biologics that can be improved with dynamic light scattering

Biologics, which are drugs and treatments derived from natural products, undergo a long development process...

Up next
Multi-parameter formulation development for an HIV-vaccine protein with direct validation of epitope binding
Multi-parameter formulation development for an HIV-vaccine protein with direct validation of epitope binding

Join Thomas Schubert, CEO of 2bind, as he walks through experiments done on the Prometheus Panta to determi...

Have a question about Prometheus?

Contact Specialist